Roche's Alzheimer's Drug Shows Promise in Mid-Stage Trials

Roche, a pharmaceutical company, has recently announced at an online investor event that their experimental drug for Alzheimer's disease, trontinemab, has shown positive results in a Phase Ib/IIa clinical trial. The drug, an investigational monoclonal antibody, is designed to target amyloid-beta, a protein associated with Alzheimer's. The study, which was led by Azad Bonni, Roche's senior vice president, demonstrated significant reduction in amyloid plaques, a key characteristic of the disease.
Trontinemab was developed using Roche's Brainshuttle technology, which allows the drug to penetrate the blood-brain barrier and achieve better distribution in the brain. The clinical trial was a dose-escalation study involving four groups of patients receiving increasing doses of the drug or a placebo. At the lowest dose of 0.2 mg/kg, amyloid levels were reduced by 20 centiloid units on average, compared to a 5-unit reduction in the placebo group. The highest dose of 3.6 mg/kg, while lacking 28-week data, showed a substantial reduction in amyloid plaques at 12 weeks, with most patients falling below the threshold for amyloid positivity.
The drug was found to be safe and well-tolerated, with only two cases of adverse effects related to amyloid-related imaging abnormalities (ARIA). These incidents were observed in patients receiving the second-highest dose. The positive findings for trontinemab come after Roche's previous setbacks with other Alzheimer's drugs, including crenezumab, which failed to meet its objectives in Phase III trials in 2022, and ganenterumab, which did not meet its primary endpoints in 2022 studies.
In addition to the Alzheimer's research, Roche also presented long-term data on prasinezumab, another drug candidate for Parkinson's disease, which showed potential in slowing motor progression. However, the company noted that these results are preliminary and require further validation through independent trials. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!